The FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Biosciences, pulverising its share price. The halt of the IGNITE DMD trial was prompted by ...
Andrew Beattie was part of the original editorial team at Investopedia and has spent twenty years writing on a diverse range of financial topics including business, investing, personal finance, and ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results